# Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT

> **NCT04504318** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 82 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Apixaban 2.5 MG Oral Tablet
- **DRUG:** Enoxaparin 40Mg/0.4mL Prefilled Syringe

## Key facts

- **NCT ID:** NCT04504318
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2024-06-19
- **Final completion:** 2024-06-19
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504318, "Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04504318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*